Pichl Daniel 4
4 · SpringWorks Therapeutics, Inc. · Filed Feb 12, 2025
Insider Transaction Report
Form 4
Pichl Daniel
Chief People Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-10$27.64/sh+13,750$380,050→ 64,512 total - Exercise/Conversion
Common Stock
2025-02-10$27.64/sh+16,000$442,240→ 80,512 total - Sale
Common Stock
2025-02-10$54.25/sh−9,000$488,260→ 57,762 total - Sale
Common Stock
2025-02-10$57.15/sh−7,000$400,072→ 50,762 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-10−13,750→ 31,250 totalExercise: $27.64Exp: 2033-01-05→ Common Stock (13,750 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-10−16,000→ 32,750 totalExercise: $27.64Exp: 2033-01-05→ Common Stock (16,000 underlying) - Sale
Common Stock
2025-02-10$53.02/sh−13,750$728,998→ 66,762 total
Footnotes (6)
- [F1]The transactions reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on May 21, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.00 to $54.515. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.00 to $57.36. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F5]This option shall vest in 48 equal monthly installments subject to continued service to the Issuer by the Reporting Person.
- [F6]Twenty-five percent (25%) of this option shall vest and become exercisable on January 5, 2024, with the remaining seventy-five percent (75%) to vest in thirty-six (36) equal monthly installments thereafter subject to continued service to the Issuer by the Reporting Person.